Ann‐Lii Cheng
National Taiwan University of Science and Technology(TW)University of California, Los Angeles(US)Tianjin University(CN)National Taiwan University(TW)National University of Defense Technology(CN)Sichuan University(CN)St. Luke's Medical Center(PH)National Taiwan University Hospital(TW)State Key Laboratory of Oral DiseasesTaipei Medical University(TW)Xi'an Jiaotong University(CN)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma(2020)6,911 cited
- → Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial(2008)5,801 cited
- → Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial(2018)5,305 cited
- → Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial(2016)3,612 cited
- → Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial(2018)2,498 cited
- → Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma